Page 2 - Carnot
P. 2
A Carnot Institute Devoted To
Lymphoma: Creating Synergies,
Initiating Partnerships, Accelerating
Translational Research
Our 4 R&D pillars at the core
of innovation
1 Research and validation of new 3 Early monitoring of activity
biological targets and lymphoma (early pharmacodynamic
in in vitro and in vivo models > markers, circulating DNA,
to develop new preclinical drug immunomonitoring) > to accelerate
candidates. translational research.
2 Identification, validation, 4 Optimization and exploitation
patenting and licensing of of clinical research related tools
blood and tissue biomarkers > to accelerate development,
> to improve diagnosis, guide registration and market access of
therapy decisions and predict drug candidates.
tumor responses.
